Uncategorized

Otsuka’s ADHD approval opens up new drug class with $615M opportunity

Published

on

Otsuka Pharmaceutical plans to launch Simtriyo—the first norepinephrine, dopamine, serotonin reuptake inhibitor—later this year following scheduling by the U.S. Drug Enforcement Agency.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version